Human Requirements for the Nutrient Choline

Not Applicable

Completed

• Conditions: Postmenopausal Women
• Interventions: Other: Estrogen plus choline depletion diet; Other: Placebo plus choline depletion diet; Other: Pre-menopausal women with SNPs given a low choline diet

• Registration Number: NCT00065546
• Lead Sponsor: University of North Carolina, Chapel Hill

Brief Summary

The purpose of this study is to increase our understanding of how much choline humans need to get from their diet. Choline is an essential nutrient found in many foods, including eggs and milk. In addition to dietary sources, choline can be made in the liver. Choline is important in making membranes or wrappers for all the cells in the body and for making chemicals that allow nerve cells to work properly. In a previous study we found that the dietary requirement for choline varies greatly from person to person. This was caused, in part, by how much estrogen a person has and their genetic makeup. We are conducting this study to explore how estrogen levels and specific differences in genes influence choline requirements so that we can refine the dietary recommendations for this nutrient.

Detailed Description

Choline is an essential nutrient essential used for the structural integrity and signaling functions of cell membranes, cholinergic neurotransmission, and lipid transport/metabolism. Choline is obtained from the diet and from endogenous biosynthesis catalyzed by the enzyme phosphatidylethanolamine N-methyltransferase (PEMT). The major premise for this proposal is that humans require a dietary source of choline and that this requirement has significant individual variation and is modulated by estrogen and common genetic polymorphisms. The promoter of the PEMT gene is estrogen responsive, and we hypothesize that estrogen status influences the dietary requirement for choline. We identified other common single nucleotide polymorphisms (SNPs) that increase or decrease the likelihood that a human will develop organ dysfunction when fed a low choline diet. Experiments are proposed that will refine our understanding of estrogen-mediated induction of the PEMT promoter; determine whether postmenopausal women treated with estrogen have a decreased susceptibility to developing organ dysfunction associated with choline deficiency; determine the prevalence of SNPs that increase susceptibility to choline deficiency in the population and examine dietary choline requirements in humans with these SNPs.

Study Timeline

• Study First Submitted: 2003-07-28
• Study First Submitted QC: 2003-07-30
• Study First Posted: 2003-07-31
• Study Start: 2007-06
• Primary Completion: 2009-09
• Status Verified: 2012-01
• Study Completion: 2012-01
• Last Update Submitted: 2012-01-05
• Last Update Posted: 2012-01-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 43

Inclusion Criteria

• Healthy
• Non-smoker
• BMI between 18 and 34
• Normal mammogram in last 12 months (post-menopausal women only)

Read More

Exclusion Criteria

• Hormone or estrogen therapy
• Allergic to soy, eggs, wheat
• History of breast, uterine, or other estrogen-dependent cancer
• Liver or kidney problems
• History of circulation, bleeding, or blood-clotting disorder
• Anemia or evidence of iron overload
• Hyperthyroidism, neurological disorder, or autoimmune disease
• Diabetes controlled by insulin
• Positive serology for HIV or Hepatitis B or C
• Alcohol or illegal drug misuse/abuse
• Pacemaker, aneurysm clip, cardiac heart valve, mechanical devices/implants
• Other metal in body (i.e. injured by a BB, shrapnel, or metallic object)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Estrogen plus choline depletion diet	Post-menopausal women randomized to receive estrogen replacement therapy.
2	Placebo plus choline depletion diet	Post-menopausal women randomized to receive a placebo.
3	Pre-menopausal women with SNPs given a low choline diet	Pre-menopausal women with specific genetic variants.

Primary Outcome Measures

Name	Time	Method
Evidence of liver or muscle dysfunction (based on elevations in CPK, AST, ALT), or increased liver fat (measured by liver MRI)	Labs measured every 3-4 days throughout 62-day trial. Liver MRI performed on study days 1, 10, 31, 52, 62.

Trial Locations

Locations (1)

University of North Carolina; 🇺🇸 Chapel Hill, North Carolina, United States